{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["9(5)"],"submitter":["Schouten RD"],"pubmed_abstract":["<h4>Background</h4>For advanced non-small cell lung cancer anti-PD-1 treatment has become standard care in first and second line treatment in recent years. Because many of the clinical trials with anti-PD-1 drugs have only recently been completed, long term follow up data of patients treated with these agents is scarce, even more so of patients treated in real life clinical care. We present long term follow up of patients treated with nivolumab.<h4>Methods</h4>Two hundred forty-eight patients with pre-treated, advanced NSCLC who received nivolumab between August 2015 and December 2018 were included in this retrospective cohort study. Overall survival and progression free survival rates were calculated for the total cohort and for subgroups defined by clinical characteristics, responses to "],"journal":["Translational lung cancer research"],"pagination":["1736-1748"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7653122"],"repository":["biostudies-literature"],"pubmed_title":["Nivolumab in pre-treated advanced non-small cell lung cancer: long term follow up data from the Dutch expanded access program and routine clinical care."],"pmcid":["PMC7653122"],"pubmed_authors":["Muller M","Egberink L","Baas P","Schouten RD","De Gooijer CJ","van Werkhoven E","van den Heuvel MM"],"additional_accession":[]},"is_claimable":false,"name":"Nivolumab in pre-treated advanced non-small cell lung cancer: long term follow up data from the Dutch expanded access program and routine clinical care.","description":"<h4>Background</h4>For advanced non-small cell lung cancer anti-PD-1 treatment has become standard care in first and second line treatment in recent years. Because many of the clinical trials with anti-PD-1 drugs have only recently been completed, long term follow up data of patients treated with these agents is scarce, even more so of patients treated in real life clinical care. We present long term follow up of patients treated with nivolumab.<h4>Methods</h4>Two hundred forty-eight patients with pre-treated, advanced NSCLC who received nivolumab between August 2015 and December 2018 were included in this retrospective cohort study. Overall survival and progression free survival rates were calculated for the total cohort and for subgroups defined by clinical characteristics, responses to ","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Oct","modification":"2025-04-19T23:40:26.263Z","creation":"2025-04-19T23:40:26.263Z"},"accession":"S-EPMC7653122","cross_references":{"pubmed":["33209597"],"doi":["10.21037/tlcr-19-698"]}}